EXHIBIT 99.1

                        EDG CAPITAL, INC. CHANGES NAME TO
                          ISOTOPE SOLUTIONS GROUP, INC.

(GARDEN CITY, NY --- NOVEMBER 20, 2001) --- EDG Capital, Inc. (OTCBB: ISTP), a
developer of nuclear pharmaceuticals for therapeutic use in the treatment of
cancer, announced today that on November 14, 2001, its shareholders approved the
change of its corporate name to Isotope Solutions Group, Inc. The change of name
was accomplished through the approval at a special meeting of shareholders of an
amended and restated certificate of incorporation. The amended and restated
certificate of incorporation also effected a number of other important changes
meant to bring the certificate of incorporation up to date, including the
authorization of a class of undesignated preferred stock and the adoption of a
provision permitting the shareholders to act by less than unanimous written
consent.

"Our new corporate name, Isotope Solutions Group, Inc., and our new trading
symbol, ISTP, more accurately symbolize our mission as a biopharmaceutical
development company," said Jack Schwartzberg, Chief Executive Officer, President
and Chairman.

Isotope Solutions Group, Inc.'s shareholders also approved at the special
meeting an increase in the shares of common stock that may be awarded under the
corporation's 2000 Long-Term Incentive Plan to 2,500,000 shares, as well as
certain proposed payments and/or property transfers to be made pursuant to the
employment agreements between Isotope Solutions Group and each of Jack
Schwartzberg and Shraga David Aranoff, Vice President, Chief Operating Officer
and Treasurer, the reimbursement and termination provisions of the option
agreements between Isotope Solutions Group and each of Jack Schwartzberg and
Shraga David Aranoff, and the vesting provisions of the 2000 Long-Term Incentive
Plan for purposes of excluding such payments and/or property transfers from the
"parachute payment" provisions of Sections 280G and 4999 of the Internal Revenue
Code of 1986. Approval of these proposed payments and/or property transfers may
enable the corporation to deduct these payments and property transfers, which
consist principally of severance pay and the acceleration of options, from its
taxes as compensation expense in the event of a change in control of the
corporation. The corporation is not presently aware of any proposed or
contemplated change of control of the corporation.

ABOUT ISOTOPE SOLUTIONS GROUP, INC. Through its wholly-owned subsidiary, Isotope
Solutions, Inc., Isotope Solutions Group, Inc. is engaged in the research,
development and testing of nuclear pharmaceuticals for therapeutic use in the
treatment of the most lethal forms of cancer. Internationally renowned
clinicians, who are under management contracts with Isotope Solutions, Inc.,
conduct research for the company.

Legal Disclaimers: This press release may contain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual performance and
results of operations may differ materially from those projected or suggested in
the forward-looking statements. The forward-looking statements contained herein
represent Isotope Solutions Group, Inc.'s judgment as of the date of this
release, and Isotope Solutions Group, Inc. cautions investors not to place undue
reliance on such statements.


                                       3




CONTACT:  ISOTOPE SOLUTIONS GROUP, INC., NEW YORK
          Shragie David Aranoff
          Vice President
          516/222-5154
          shragie@isotopesolutions.com

          or

          RUBENSTEIN ASSOCIATES, INC.
          Patricia Amerman
          Vice President
          212/843-8049
          pamerm@rubenstein.com


























                                       4